Ftse Mib
33.778,74
-1,51%
DAX
17.932,17
-1,10%
S&P 500
5.063,65
-1,03%
NASDAQ Composite
15.814,34
-1,06%
Bitcoin
60.155,94
-5,77%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Halozyme Therapeutics Incorporated (HALO) Halozyme Therapeutics Incorporated (HALO) Notizie

Halozyme Therapeutics Incorporated

HALO
38,41
-0,36 (-0,93%)
Ultimo aggiornamento: 19:03:21
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
25/4/202422:45PRNUSMahesh Krishnan Elected to Halozyme's Board of Directors
23/4/202414:30PRNUSHalozyme to Report First Quarter 2024 Financial and..
04/3/202422:13EDGAR2Form PRE 14A - Other preliminary proxy statements
29/2/202400:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202422:07EDGAR2Form 144 - Report of proposed sale of securities
27/2/202423:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202423:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202423:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202422:08EDGAR2Form 144 - Report of proposed sale of securities
27/2/202414:30PRNUSHalozyme to Participate in Upcoming Investor Conferences
21/2/202400:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202400:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202400:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202400:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202422:07EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
20/2/202422:03EDGAR2Form 8-K - Current report
20/2/202422:01PRNUSHALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL..
16/2/202423:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202423:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202423:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202412:19EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/2/202422:30PRNUSHalozyme To Report Fourth Quarter and Full Year 2023..
29/1/202422:15PRNUSHalozyme Announces Takeda Received European Commission..
23/1/202417:52EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
18/1/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/1/202414:30PRNUSHalozyme Announces argenx Received Approval in Japan for..
17/1/202422:56EDGAR2Form 144 - Report of proposed sale of securities
17/1/202414:10EDGAR2Form 8-K - Current report
16/1/202422:26EDGAR2Form 144 - Report of proposed sale of securities
16/1/202414:15PRNUSHalozyme Announces Takeda Receives FDA Approval for HYQVIA®..
16/1/202407:15PRNUSHalozyme Announces Roche Receives European Commission..
12/1/202415:25PRNUSHalozyme to Host Investor Business Forum and Long-Term..
05/1/202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/12/202301:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202322:40EDGAR2Form 144 - Report of proposed sale of securities
12/12/202322:21EDGAR2Form 144 - Report of proposed sale of securities
27/11/202314:00PRNUSHalozyme to Present at Upcoming Investor Conferences
16/11/202322:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/11/202315:00PRNUSHalozyme Announces argenx Receives European Commission..
15/11/202322:17EDGAR2Form 144 - Report of proposed sale of securities
14/11/202322:19EDGAR2Form 144 - Report of proposed sale of securities
06/11/202322:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202322:04EDGAR2Form 8-K - Current report
06/11/202322:01PRNUSHALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING..
06/11/202313:30PRNUSHalozyme and Acumen Pharmaceuticals Enter Global..
30/10/202323:35PRNUSHalozyme To Report Third Quarter 2023 Financial and..
19/10/202313:15PRNUSPositive Topline Results Reported from Bristol Myers..
Apertura: 38,54 Min: 38,21 Max: 39,03
Chiusura: 38,77

La tua Cronologia

NASDAQ
HALO
Halozyme Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network